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Zusammenfassung 
Hintergrund 
Der Begriff „Access to Medicines“ war bis vor wenigen Jahren mit der Dis-
kussion um günstigere (generische) lebenswichtige Medikamente (HIV, Tu-
berkulose, etc.) in Entwicklungsländern verbunden. Seit einiger Zeit befas-
sen sich nun auch westliche Länder und Institutionen (OECD, Europäische 
Commission, etc.) mit dem „Zugang zu Medikamenten“, um den „nicht-nach-
haltigen“ Medikamentenpreisen entsprechende Lösungen entgegenzusetzen.  
Die Ausgaben für Forschung & Entwicklung (F&E) werden von den Her-
stellern zumeist als Begründung verwendet, um die hohen Preise zu recht-
fertigen. Die eigentliche – ressourcenaufwändige und risikoreiche – Grund-
lagenforschung findet aber überwiegend im öffentlichen Sektor (in Univer-
sitäten und entsprechenden öffentlich-finanzierten Forschungseinrichtun-
gen) statt. Wenig publiziertes Wissen zu öffentlichen Ausgaben liegt hinge-
gen bislang vor. Das Projektziel ist, die öffentlichen Beiträge zu Arzneimit-
telforschung und -entwicklung zu erheben und damit einen Beitrag zur Dis-
kussion um „Return on Investment of Public Investment“ zu leisten. 
 
Methode 
Das Projekt erfolgte zwei-stufig: In Phase 1 wurde an der Entwicklung einer 
Methode (Suchstrategie und Quellen) gearbeitet, um den Beitrag der öffent-
lichen Forschungsförderung bei der Entwicklung neuer Medikamente syste-
matisch zu ermitteln. In Phase 2 wurde die Methode des in Phase 1 entwickel-
ten Analyseansatzes anhand von drei ausgewählten Arzneimitteln pilotiert. 
Für die Pilotierung wurden pädiatrische Orphan Drugs (Spinraza®, Brineu-
ra®, Crysvita®), die 2017 von der Europäischen Arzneimittel-Agentur (EMA) 
zugelassen wurden, ausgewählt.  
 
Ergebnisse 
Ergebnis Methode: ein mehrstufige Suchprozess wurde als Leitfaden für Su-
chen nach öffentlichen (und philanthropischen) Forschungsförderungen ent-
wickelt:  
 Schritt 1: Identifikation aller generischen wie molekularer Namen und 
Begriffe des Arzneimittels entlang des gesamten F&E Prozesses in 
Datenbanken (DrugBank, ChEMBL, Therapeutic Target Database). 
 Schritt 2: Systematische Suche nach Informationen zum Entwicklungs-
pfad vor Zulassung und entsprechenden Forschungsförderungen wie 
Patentierungen in den Entwicklungsschritten in multiplen Datenban-
ken und Studienregistern (Orphanet; Studienregister: WHO interna-
tional trials registry, US-Clinical Trials.Gov; EU clinical trials registry; 
Patent-Datenbanken: FDA orange book, Espacenet, Health Canada 
Patent Database; Zulassungsinstitutionen: FDA, EMA; Bibliographi-
sche Datenbanken: PubMed, Google). 
 Schritt 3: Systematische Suche nach Forschungsförderungen (NIH-Re-
PORTER-Database, CORDIS, IMI, EDCTP, diverse philanthropische 
Quellen, etc.). 
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Ergebnis Pilotierung: die Suchstrategie wurden an drei pädiatrische Orphan 
Drugs pilotiert, wobei der Zeitraum zwischen der Identifikation des Mole-
küls/Wirkmechanismus/Genidentifizierung und des Jahres der Zulassung als 
Zeitrahmen angenommen wurde: 
 Nusinersen/Spinraza®: mithilfe eines Dokuments des National Institu-
te of Neurological Disorders and Stroke (NINDS) konnte die Stufen 
der Entwicklung von Nusinersen detailliert nachverfolgt werden. Es 
wurden > 40 öffentlich, aber auch philanthropisch geförderte Projek-
te identifiziert. Insgesamt wurden Förderungen für SMA F&E in der 
Höhe von € 165 Million (davon € 20 Million direkt Produkt-bezogen) 
gefunden.  
 Cerliponase alpha/Brineura®: mithilfe eines Dokuments des National 
Institute of Neurological Disorders and Stroke (NINDS) konnte der 
Zeitpunkt der frühen Entwicklung identifiziert werden. Es wurden 
> 20 öffentlich sowie einige philanthropisch geförderte Projekte iden-
tifiziert werden. Es konnten öffentliche Forschungsfördersummen ge-
funden werden (nur Produkt-bezogen € 31 Million) aber keine philan-
thropische Summen. 
 Burosumab/Crysvita®: Aufgrund der Entwicklung des Wirkstoffs in Ja-
pan konnten keine/kaum Informationen in englischer Sprache gefun-
den werden. Es wurden viele öffentlich sowie einige philanthropisch 
geförderte Projekte identifiziert, jedoch nur wenige konkrete Summen 
(€ 26 Million in englischen-sprachigen Quellen, vor allem in der Grund-
lagenforschung). 
 
Schlussfolgerung 
Die Recherchen zu öffentlichen und philanthropischen F&E Förderungen 
erwiesen sich als sehr zeitaufwändig. Hindernisse waren ein Mangel an Trans-
parenz in den diversen Datenbanken und Quellen und/oder Komplexität der 
Suchfilter (Eingrenzung des Suchzeitraums und Unterscheidung zwischen 
Grundlagenforschung und Forschung zur Produktentwicklung) sowie Sprach-
barrieren. Die Suchstrategien mussten individuell angepasst werden, die Er-
gebnisse sind sehr unterschiedlich. An weiteren Pilotierungen wie einer Ver-
feinerung der Suchstrategie wird gearbeitet. 
 
  
Ergebnis Pilotierung  
Nusinersen/Spinraza® 
Cerliponase alpha/ 
Brineura® 
Burosumab/Crysvita® 
Mangel an Transparenz 
bei Quellen 
Komplexität der 
Suchfilter 
weitere Pilotierungen 
mit Verfeinerung der 
Suchstrategie geplant 
Executive Summary 
LBI-HTA | 2019 7 
Executive Summary 
Background 
The term “access to medicines” was until a few years ago associated with the 
discussion surrounding cheaper (generic) vital drugs (HIV, tuberculosis, etc.) 
in developing countries. For some time, Western countries and institutions 
(OECD, European Commission, etc.) have also begun to focus on “access to 
medicines” in an attempt to counteract “unsustainable” drug prices.  
Expenditure on research and development (R & D) is mostly used by manu-
facturers as a justification for high prices. The real – resource-consuming and 
high-risk – basic research takes place mainly in the public sector (in univer-
sities and corresponding publicly funded research institutions) instead. Lit-
tle publicized knowledge on public spending, however, exists so far. The pro-
ject objective is to collect information on public contributions to drug re-
search and development and thus contribute to the discussion on "Return on 
Investment of Public Investment". 
 
Methods 
The project was carried out in two stages: in Phase 1, a methodology (search 
strategy and sources) was developed to systematically identify the contribu-
tion of public research funding to the development of new drugs. In Phase 2, 
the methodology of the Phase 1 analytical approach was piloted using three 
selected drugs. Pediatric Orphan Drugs (Spinraza®, Brineura®, Crysvita®), 
which were approved by the European Medicines Agency (EMA) in 2017. 
 
Results 
Results on Methods: A multi-level search process was developed as a guide 
to searches for public (and philanthropic) research funding: 
 Step 1: Identification of all generic and molecular names and terms of 
the drug along the entire R & D process in databases (DrugBank, Ch-
EMBL, Therapeutic Target Database). 
 Step 2: Systematic search for pre-marketing pathway information, and 
related research funding such as patenting, using multiple databases 
and trial registries (Orphanet, WHO Clinical Trials.Gov, Patent Da-
tabases: FDA Orange Book, Espacenet, Health Canada Patent Data-
base; Regulatory Institutions: FDA, EMA; Bibliographic Databases: 
PubMed, Google). 
 Step 3: Systematic search for corresponding research funding amounts 
(NIH-RePORTER-Database, CORDIS, IMI, EDCTP, various phil-
anthropic sources, etc.). 
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Results of pilots: the search strategy was piloted on three paediatric orphan 
drugs, taking the period between the identification of the molecule/ mecha-
nism of action/gene and the date of market authorisation as the relevant time 
frame: 
 Nusinersen/Spinraza®: Nusinersen’s scientific developmental stages 
were identifiedusing a document from the National Institute of Neu-
rological Disorders and Stroke (NINDS). In total we were able to iden-
tify > 40 publicly but also philanthropically funded projects. In total, 
subsidies for SMA R & D in the amount of € 165 million (of which 
€ 20 million were product-related) were found. 
 Cerliponase alpha/Brineura®: Using a document from the National In-
stitute of Neurological Disorders and Stroke (NINDS), it was possible 
to identify the time of early scientific development. We could identify 
> 20 public and some philanthropic funded projects from this date, 
but the philanthropic contribution was harder to quantify. We put a 
conservative estimate of public funding (i.e. national and internation-
al funding, excluding charities) for this product at € 31 million. 
 Burosumab/Crysvita®: Regarding the development of the active ingre-
dient in Japan, little/no information could be found in English. Many 
public and some philanthropically funded projects have been identi-
fied. The sum of publically funded, mostly basic research, is estimated 
at € 26 million (English-language sources only). 
 
Conclusions 
The research on public and philanthropic R & D funding proved to be very 
time consuming. Obstacles were a lack of transparency in the various data-
bases and sources and/or complexity of the search filters (narrowing the 
search period and distinguishing between basic research and product devel-
opment research) and language barriers. The search strategies had to be 
adapted individually, the results are very different. Further piloting such as 
a refinement of the search strategy is underway. 
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lack of transparency of 
sources + complexity of 
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1 Methodology 
1.1 Introduction 
This document describes the methodology that will be implemented to assess 
the public or philanthropic contribution to the drug discovery and develop-
ment process, following on from published work in this area [1-5].  
The focus is on basic and early-stage research as well as early clinical trials. 
This includes what is termed step 1 of the drug development process, known 
as discovery and development, and step 2, termed preclinical research. There 
may also be phase 0 clinical trials (exploratory studies that often use only a 
few small doses of a new drug in a few patients, designed to speed up and 
streamline the drug approval process) as well as phase 1-3 clinical studies up 
to the date of market authorisation, which form part of step 3, clinical re-
search1, 2. 
 
 
1.2 Case studies 
Up to 3 case studies are planned initially, before refinement or affirmation 
of methodology. Products will be chosen using the EMA list of new active 
substances relating, in the first instance, to the area of orphan medicine, pre-
ferably paediatric-relevant products. 35 new active substances were recom-
mended for approval by EMA in 2017, 13 of which were orphan products: 
Bavencio, Besponsa, Lutathera, Rydapt, Zejula (all cancer products); Prevy-
mis (infections); Crysvita, Xermelo (endocrinology); Brineura, Oxervate, Spin-
raza (neurology), Refixia (haematology), Alofisel (hepatology/gastroenterol-
ogy). Four of these orphan products were declared by the EMA to be medi-
cines for children representing an outstanding contribution to public health: 
Brineura, Spinraza, Alkindi and Crysvita. These four products will consti-
tute the first case studies.  
After these have been completed, further suitable case studies will be deter-
mined and will potentially include non-orphan and non-paediatric products. 
The following information will be extracted from the identified funding or-
ganisations (as far as possible): study title; date of funding; amount of fund-
ing; stage of development/content of project; lead institution; principal in-
vestigator; co-operating institutions. The results will be presented in tabular 
form. 
 
                                                             
1 https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-
development-process 
2 https://www.ecmcnetwork.org.uk/what-are-clinical-trials 
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Inclusion and exclusion criteria 
All academic papers, grey literature and online information relating to the 
development of the drug in question that took place before the date of mar-
keting authorisation will be considered relevant, if there is any mention of 
public or philanthropic funding. There is no restriction relating to the type 
of article (e.g. trial or review) or the quality of the publication. The aim is to 
develop a picture of the development of the drug and for that reason a broad 
definition of potential relevant information is used. When a product has 
multiple indications, public contributions to all indications prior to date of 
market approval will be included.  
 
 
1.3 Definition of drug terms 
The first step is to determine all the names under which the drug was known 
during the development, including the relevant molecular terms. For this 
purpose, the following databases are searched and names relating to the in-
ternational non-proprietary name, chemical name and mechanism action of 
the product will be documented.  
Table 1.3-1: Databases for searches of drug-relevant information 
DrugBank 
https://www.drugbank.ca/ 
This is a comprehensive source of bioinformatic and chemical information, 
combining detailed data on drugs (e.g. synonyms, chemical, pharmaco-
logical and pharmaceutical data) with detailed information on target 
connections (targets) e.g. sequence, structure, metabolic pathways. 
ChEMBL 
https://www.ebi.ac.uk/chembl/ 
Database of bioactive molecules with drug properties that includes 
synonyms, brand names, generic names and pre-commercial company 
names, as well as MeSH terms related to NCBI Query Translation. 
Therapeutic Target Database 
(TTD) 
http://bidd.nus.edu.sg/group/cjttd/ 
Database that provides information about known and researched 
therapeutic proteins and nucleic acid targets, the targeted disease, 
pathway information and the corresponding drugs for each of these 
targets. This database also contains links to relevant databases containing 
information on target function, sequence, 3D structure, ligand binding 
properties, enzyme nomenclature and drug structure, therapeutic class, 
clinical development status. 
 
 
1.4 Search strategy 
A combination of search strategies is used to generate a picture of the prod-
uct and the development path it underwent, using the product-related search 
terms identified in the previous stage. These searches are detailed below: 
 Orphanet https://www.orpha.net/consor/cgi-bin/index.php?lng=DE:  
for orphan drugs. This is a database that brings together resources on 
rare diseases and drugs for the treatment of rare diseases (so-called 
orphan drugs) to improve their diagnosis and treatment. Orphanet was 
initiated in 1997 by the French Ministry of Health and the Institut 
national de la santé et de la recherche médicale (INSERM) and is now 
run by a consortium of European partner countries under French lead-
ership and with support from the European Union. 
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The following three databases are searched for information on clinical trials 
prior to marketing authorisation:  
 WHO international trials registry: http://apps.who.int/trialsearch/ 
US-Clinical Trials.Gov: https://www.clinicaltrials.gov/ and EU clin-
ical trials registry/EudraCT: https://www.clinicaltrialsregister.eu/ctr-
search/search. Also clinical study registries of relevant pharmaceutical 
companies are checked, where available: e.g. Fehler! Hyperlink-
Referenz ungültig.. The aim of searching these clinical trials data-
bases is primarily to find potentially relevant clinical studies.  
 Patent database searches are conducted to try to ascertain whether uni-
versities, research groups or other organisations aside from the phar-
maceutical company are listed. The following databases for the USA 
and Europe will be used: FDA orange book US PTO :   
https://www.accessdata.fda.gov/Scripts/cder/ob/index.cfm; 
https://www.uspto.gov/, the Espacenet patent database:   
https://worldwide.espacenet.com/ and Health Canada Patent Database: 
https://www.canada.ca/en/health-canada/services/drugs-health-
products/drug-products/patent-register.html.  
 Also check the following for information on patents:  
 Medicines Patent Pool Patent Search: https://www.medspal.org/, 
 Pat-informed database: https://www.wipo.int/pat-informed/en/, 
 U.S. Patents with US Government Rights Declared 
http://drugdatabase.info/databases/us-patents-government-
rights-declared/ 
 EDGAR Company Filings to identify company records  
which lists relevant patent numbers for the products: 
https://www.sec.gov/edgar/searchedgar/companysearch.html 
(in particular the 10-K which sometimes lists patents) 
 Websites of product approval organisations 
 FDA Label: https://www.drugbank.ca/drugs/DB13173 includes 
drug information (description, pharmacology, clinical studies,  
indications and contraindications, ...), 
 EMA label https://www.ema.europa.eu/en/medicines/human/ 
which similarly provides drug information (see particularly the 
EMA assessment report). 
 Websites of the pharmaceutical companies: The website of the phar-
maceutical company marketing the product is searched for relevant 
information; including a check of the annual reports available online 
(is there any mention of R&D expenses or licenses/co-operations re-
garding external laboratories/universities?)  
 Bibliographic database:  
 PubMed is searched using an ontology of drug names restricted to 
publications dated before the date the product was first marketed. 
There are no restrictions on the type of article (trial or review for 
example), nature of the trial (preclinical or clinical) or the quality 
of the review or study. Reference lists are searched for additional 
relevant papers. 
 Google internet search: The internet is searched using the various 
terms identified for the product. The aim of this search is, in par-
ticular, to identify review stories relating to the product including 
any “success stories” relating to academic developments.  
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1.5 Funding information 
The sources listed in section 1.4 are used to look for indications of grants or 
funding mechanisms or researchers/research groups involved in the develop-
ment and testing of the product. Where the involvement of a funding body is 
indicated, the database/website of the funding organisation will be searched 
for detailed information on the nature and amount of funding. It is expected 
that the following funding bodies listed will be relevant to many of the prod-
ucts (note: the funding organisations will not be searched if there is no indi-
cation from the sources in 1.4 that they provided funding):  
 NIH-RePORTER-Database 
 EU-funding (CORDIS, H2020) 
 Innovative Medicines Initiative (IMI) 
 Army Grants 
 European & Developing Countries Clinical Trials Partnership 
(EDCTP)  
 National funding organisations where mentioned such as Medical 
Research Council (UK), Welcome Trust (UK), CNRS (France), 
BMBF (Germany) … 
 Philanthropic organisations such as Bill & Melinda Gates Foundation. 
 Others as determined by the search results … 
 
 
1.6 References 
[1] Cleary E. et al, Contribution of NIH funding to new drug approvals  
2010-2016. www.pnas.org/cgi/doi/10.1073/pnas.1715368115. 
[2] European Medicines agency. Human medicines highlights 2017. 
https://www.ema.europa.eu/en/documents/report/human-medicines-
highlights-2017_en.pdf.  
[3] Head M. et al, UK investments in global infectious disease research  
1997-2010: a case study. Lancet Infect Dis 2013; 13: 55-64. 
[4] Schuhmacher A. Changing R&D models in research-based pharmaceutical 
companies. Journal of Translational Medicine 2016; 14: 105 
[5] Stevens A. et al, The role of pubic-sector research in the discovery of drugs 
and vaccines. NEJM 2011; 364(6): 563-541. 
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2 Case Studies 
The detailed results are summarized in an excel-database.  
They can be provided on request. 
 
 
2.1 Nusinersen (Spinraza®): Summary of results 
Background 
The aim of this piece of research was to identify the non-industry-financed 
component of R&D activities in the development of Spinraza® (a product for 
treating children and adults with spinal muscular atrophy (SMA), marketed 
by Biogen. The focus on the research is on project funding through public 
funding bodies and contributions from philanthropic/charitable organisa-
tions. We attempted to ascertain the level of funding using bibliographic 
and/or website sources. No qualitative methods were used. Not included are 
tax concessions on costs arising from any research activities carried out by 
the pharmaceutical company.  
 
Methods 
The methods outlined above were followed. Not included in the methods: es-
timation of amount of tax deductions (orphan drug tax credit or priority re-
view voucher). Method strategies were developed in an iterative process fol-
lowing exchanges of ideas between international researches in regular web 
conferences. Research activities generally also continue beyond the date of 
market authorization, which cannot therefore be attributed to development 
costs. We therefore used 2017 as the cut-off date for potentially relevant pro-
jects and funding. We identified 2007 as the relevant year for product-spe-
cific development. According to the National Institute of Neurological Disor-
ders and Stroke (NINDS) timeline document, this was the time point at which 
researchers first described the antisense oligonucleotides that were to become 
nusinersen.  
 
Results 
Particularly useful databases regarding the identification of projects research-
ing SMA therapies was “Orphanet”. Regarding funding information, the NIH 
(via the NIH reporter database) and the Canadian Institutes of Health Re-
search (CIHR) as well as from the charity side, the Muscular Dystrophy As-
sociation (MDA), provided detailed information on the level for funding pro-
vided for projects they supported. The NINDS timeline document that de-
tailed NINDS/NIH support for product development (identified through the 
google search) was a useful source. The 10-k report identified via the US Se-
curities and Exchange Commission Filings was also helpful in identifying 
patent numbers related to the product, which enabled further searching in 
the Orange Book and patent databases. Through Pubmed only 1 additional 
project was identified (from a total of 11 hits generated up to market approv-
al date) that had not already been identified through other sources.  
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National/international funding bodies 
 6 projects funded by Canadian Institute of Health Research (CIMR) 
for a total of Can $ 3,269,130. 
 3 National Institute of General Medical Sciences (NIGMS) or Nation-
al Institute of Neurological Disorders and Stroke (NINDS) for a total 
of US $ 11,117,535 plus an additional 7 projects conducted by the 2 
main researchers named in the patent projects for an additional   
$ 11,136,414. 
 E-Rare EU calls 1 project funded (amount not given). 
 1 BMBF (German national funding programme) funded project 
€ 387,854; 1 project was co-funded by the Deutsche Forschungsgesell-
schaft (DFG, no information on funding amount available). 
 Other national European funding bodies: Italian (Fondazione Telethon: 
2 projects) and French (Association Franfaise contre les Myopathies, 
the Actions Concertees-Science du Vivant, the Institut Electricite San-
te, the Groupement de Recherches et d’Etudes sur les Genomes and 
the Programme Hospitalier de Recherche Clinique) national funding, 
although no funding amounts could be identified on the websites of 
these organisations. 
Charity funding 
 Details could be found on 15 Muscular Dystrophy Association (MDA) 
funded projects totalling $ 3,768,516. On the MDA website it is claimed 
that MDA has invested more than $ 45 million in SMA research  
 Families of SMA/Cure SMA (USA) was involved in supporting 4 pro-
jects and Kids’ Cures in 1 project. Here the exact funding amount is 
unavailable. 1 project funded by Families of SMA amounted to   
$ 381,138.  
 It is stated in the Cure SMA annual report, that funding for research 
projects in 2018 totalled 5 million US $ (on various Cure SMA web-
site postings, specific projects totalling 1 Million US $ are detailed, 
together with the names of the recipients). 
 SMA Europe lists a number of projects funded in this area before the 
date of market authorization (although there is no description of the 
projects, which makes an exact assignment to the medication impos-
sible); these total just over € 3 Million.   
 According to its website, the Spinal Muscular Atrophy Foundation 
(SMA Foundation) has spent around $ 150 Million on basic, transla-
tional and clinical research since its inception in 2003.  
Final figure 
Converting all monetary amounts into a common Euro currency, leads to a 
total funding of estimate of around € 165 Million for research into therapies 
for SMA. Taking a very conservative approach, i.e. just including projects 
named in the patents (or conducted by the same researchers named in the 
patents) or named specifically in development documents, around just over 
€ 20 Million can be directly attributable to Spinraza®. 
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Conclusions 
The NINDS timeline document provided an overview of the period of drug 
development and was a useful background reference. Through patents and 
the NINDS timeline document, a number of NIH-funded research projects 
could be identified. Charitable and philanthropic organisations often named 
a total figure invested in research into therapies for SMA. To what extent 
these can be attributed to the development of specific pharmaceuticals (as op-
posed to basic research, which can be used for the development of all phar-
maceuticals in this area) is difficult to estimate. For instance there are now 
two pharmaceutical products that have been developed for SMA which will 
have both used the results of basic research (at the time of writing, informa-
tion that the new SMA treatment from Novartis “Zolgensma” – likely to be 
the world’s highest price for a single treatment– has received approved by the 
FDA, hit the headlines)3.  
 
 
2.2 Cerliponase alpha (Brineura®): Summary of results 
Background 
The aim of this case study was to identify the non-industry-financed compo-
nent of R&D activities in the development of Cerliponase alfa (international 
nonproprietary name), marketed internationally as Brineura® by the phar-
maceutical company BioMarin. Cerliponase alfa is an enzyme replacement 
therapy (ERT) that delivers TPP1 directly to the brain of children with Neu-
ronale Ceroid-Lipofuszinosen (CLN2) disease and is approved to slow the 
loss of walking or crawling ability in children with CLN2 disease who are 
three years of age and older. The focus of this research is on identifying pro-
ject funding through public funding bodies and contributions from philan-
thropic/charitable organisations. As before, we attempted to ascertain the 
level of funding using bibliographic and/or website sources. No qualitative 
methods were used. Not included are tax concessions on costs arising from 
any research activities carried out by the pharmaceutical company.  
 
Methods 
The methods outlined above were followed. Not included in the methods: es-
timation of amount of tax deductions (orphan drug tax credit or priority re-
view voucher). Research activities generally also continue beyond the date of 
market authorization, which cannot be attributed to development costs. We 
therefore used 2017 as the cut-off date for potentially relevant projects and 
funding. As the beginning of product-specific development we identified 2000 
as the relevant year. According to the National Institute of Neurological Dis-
orders and Stroke (NINDS) timeline document, this was the time point at 
which researchers first isolated TPP1 successfully to produce recombinant 
TPP1 in a cell culture system.  
 
                                                             
3 https://www.nytimes.com/2019/05/24/health/zolgensma-gene-therapy-drug.html 
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Results 
The NINDS timeline document that detailed NINDS/NIH support for prod-
uct development (identified through the google search) was a useful source of 
project information, as was PubMed. The search for information on public 
disclosures from patent documents identified several NIH projects, as did 
searching the NIH Reporter database using the names of key principal in-
vestigators. The information from charities regarding funding was however 
not as informative as with the Spinraza® case study; as a result we were una-
ble to estimate the monetary contribution from charitable organisations.  
National/international funding bodies 
 13 National Institute for Health (NHI) research projects were  
identified, for a total of US $ 28,775,650.  
 The US National Science Foundation (NSF) funded a project  
to the amount of $ 94,931. 
 In terms of European national funding, 1 relevant project was identi-
fied as being funded by the Academy of Finland (AKA) (€ 740,120) 
and 1 by the German Ministry for Education and Research (BMBF) 
(€ 390,457). For 2 BMBF funded projects we could find no informa-
tion on the funding amount.  
 The European Union Seventh Framework Programme (FP7/2007-2013) 
funded the DEM-Child project which had an overall budget of   
€ 3,971,420. 
Charity funding 
 The Batten Disease Support and Research Organisation (BDSRA) lists 
some information on projects and project fundings (but by no means 
all) on their website or in some of the annual reports. Here an amount 
of US $ 297,391 could be identified, that specifically went into the de-
velopment of treatments for CLN2. 
 For the Neuronale Ceroid-Lipofuszinose (NCL) Stiftung, BDFA UK, 
Beyond Batten Disease Foundation, Charlotte & Hwenyth Gray Foun-
dation: no projects or funding amounts could be identified for CNL2. 
Final figure 
It was not possible to estimate a total CNL2 funding amount including char-
itable and philanthropic organisations as there was too little transparent in-
formation available online regarding charitable funding. Taking a very con-
servative approach, i.e. just including projects named in the patents (or con-
ducted by the same researchers named in the patents) or named specifically 
in development documents, around just over 31 Million Euros can be direct-
ly attributable to Brineura® through public funding. 
 
Conclusions 
The NINDS timeline document provided an overview of the period of drug 
development and was a useful background reference. Through patents and 
the NINDS timeline document, a number of NIH-funded research projects 
could be identified. Charitable and philanthropic organisations did not of-
ten name a total figure invested in research into therapies for CLN2, added 
to which Batten Disease is comprised of a number of distinct CNL diseases 
which made attribution of specific charitable contributions to therapies for 
the disease in question difficult.  
Sources:  
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2.3 Burosumab (Crysvita®): Summary of results  
Background 
The aim of this case study was to identify the non-industry-financed compo-
nent of R&D activities in the development of Burosumab, marketed interna-
tionally as Crysvita® by the pharmaceutical company Kyowa Kirin. Burosum-
ab is a monoclonal antibody that blocks X-Linked Hypophosphatemia (XLH) 
and is approved to treat children with a disorder of FGF23. The focus of this 
research is on identifying project funding through public funding bodies and 
contributions from philanthropic/charitable organisations. We attempted to 
ascertain the level of funding using bibliographic and/or website sources. No 
qualitative methods were used. Not included are tax concessions on costs aris-
ing from any research activities carried out by the pharmaceutical company.  
 
Methods 
The methods outlined above were followed. As previously described, these 
methods were developed in an iterative process, in part following the exchange 
of ideas between international researches working in this area. Research ac-
tivities generally continue beyond the date of market authorization, which 
cannot therefore by definition be attributed to development costs. We used 
2017 (date of EMA market authorization) as the cut-off date for potentially 
relevant projects and funding. We identified 1995 as the relevant year from 
which date research could be considered to be directly product related. Ac-
cording to a review article (Carpenter, 2012), a phosphate-regulating gene 
with homology to endopeptidases on the X chromosome (PHEX) was identi-
fied in the 1990s as the mutated gene in XLH; the reference given for this dis-
covery was a publication by Francis in 1995, hence this was taken as the rel-
evant year. As the first results were to show, direct product development ap-
peared to take place within Japan using Japanese public funding, details of 
which we were not able to find details in English. Therefore, we decided to 
include funding into the development and testing of animal models that took 
place after 1995 and directly enabled drug development to take place. It is im-
portant to note, that this basic science cannot readily be wholly and directly 
attributed to a specific drug. However, since we were developing and testing 
basic methodological research regarding whether public funding can be traced, 
the results of this case study also provides interesting, as yet undocumented 
information.  
 
Results 
National/international funding bodies 
 3 NIH projects were identified by the Orphanet databasetotalling  
US $ 2,129,108. 
 The PubMed search specifically for animal models revealed a further 
NIH project with funding going to the Universities of Tennessee and 
Kansas and Duke University, totaling US $5,476,755 over 16 yearsas 
well as 7 other NIH projects, that were identified as relevant from the 
PubMed search, with a total funding of US $ 20,541,065.  
 A key investigator search on NIH reporter revealed 2 further relevant 
projects within the specified time period totalling US $ 3,157,908.  
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 In total, therefore, NIH funding of basic research to the value of  
US $ 25,828,081 was identified.  
 1 Patent and 3 pubmed publications (Aono et al, 2009; Shimada et al, 
2004; Yamazaki et al, 2008) referred to diverse projects that had re-
ceived grants from the Ministry of Education, Culture, Sports, Science 
and Technology of Japan and from the Ministry of Health, Labor and 
Welfare of Japan as well as the Japan Society for the Promotion of Sci-
ence. It was not however possible to ascertain funding amounts for 
these projects. 
 The Japan Foundation for Pediatric Research was named in 1 publica-
tion (Kawai et al, 2013) identified via the Pubmed search but no fund-
ing information was found. Grants-in-Aid for Scientific Research from 
the Japanese Society for the Promotion of Science were involved in the 
funding of the work by Miyagawa; here a database of research pro-
jects was available in English but without funding amounts specified. 
 Project funding by the Austrian Science Fund € 423,832.50 awarded 
to Reinhold Erben between 2011 and 2016 was identified via the phar-
maceutical company’s website. 
 Genome Canada and the Ontario Genomic Institute as well as the Ca-
nadian Institutes of Health Research, Centre for Modeling Human 
Disease grant were named in Owen (2012), however no funding details 
could be found. A Canadian Institutes of Health Research funded pro-
ject was identified to the value of Can $ 709,152 (Larsson, 2014). 
 The Swedish Research Council and Swedish Society of Medicine part 
funded the work by Larsson. 
Charitable funding 
 The Ralph W & Grace M Showalter Research Trust Fund part-funded 
research work as noted in the publication by Clinkenbeard (2016). 
The Showalter Research Trust was also named in the funding of the 
work published by Farrow et al (2010) and Ichikawa et al (2012).  
 An American Heart Association Postdoctoral Fellowship was referred 
to (Clinkenbeard, 2016) as was a European Society for Paediatric En-
docrinology Research Fellowship (Liu, 2016). 
 The National Kidney Foundation was involved in funding the work 
by Farrow. 
 The Indiana Genomics Initiative (Clinkenbeard, Farrow) and the Indi-
ana University School of Medicine (Ischikawa) were named as further 
sponsors; no further details are available on these sponsors/awards.  
Final figure 
Converting all monetary amounts into a common Euro currency leads to a to-
tal funding estimate of around € 26,800,000 for research into therapy develop-
ment related to Burosumab. The bulk of the known, specified funding was from 
the NIH (here we only included basic research that took place after the relevant 
mutated XLH gene had been discovered); details into the often cited contri-
bution of Japanese sources to product development could not be ascertained. 
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Conclusions 
Funding related directly to drug development was listed in several instances 
as coming from Japan, however it was not possible to identify English lan-
guage details related to this funding. The research identified, for which pro-
ject and funding information was documented, was more concentrated on 
basic research once the mutated gene in XLH had been discovered, which is 
a necessary precursor to drug therapy development.  
little transparency  
with Japanese sources 
was found  
  
 
 
